These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1397 related articles for article (PubMed ID: 18462091)

  • 21. Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin.
    French GL
    J Antimicrob Chemother; 2006 Dec; 58(6):1107-17. PubMed ID: 17040922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of an outbreak of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in a French hospital.
    Mallaval FO; Carricajo A; Delavenna F; Recule C; Fonsale N; Manquat G; Raffenot D; Rogeaux O; Aubert G; Tous J
    Clin Microbiol Infect; 2004 May; 10(5):459-61. PubMed ID: 15113326
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.
    Hidayat LK; Hsu DI; Quist R; Shriner KA; Wong-Beringer A
    Arch Intern Med; 2006 Oct; 166(19):2138-44. PubMed ID: 17060545
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1997 Aug; 46(33):765-6. PubMed ID: 9272582
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.
    Steinkraus G; White R; Friedrich L
    J Antimicrob Chemother; 2007 Oct; 60(4):788-94. PubMed ID: 17623693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study.
    Florescu I; Beuran M; Dimov R; Razbadauskas A; Bochan M; Fichev G; Dukart G; Babinchak T; Cooper CA; Ellis-Grosse EJ; Dartois N; Gandjini H;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i17-28. PubMed ID: 18684703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of both clinical features and mortality risk associated with bacteremia due to community-acquired methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus.
    Wang JL; Chen SY; Wang JT; Wu GH; Chiang WC; Hsueh PR; Chen YC; Chang SC
    Clin Infect Dis; 2008 Mar; 46(6):799-806. PubMed ID: 18266610
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Approaches to serious methicillin-resistant Staphylococcus aureus infections with decreased susceptibility to vancomycin: clinical significance and options for management.
    Lewis JS; Ellis MW
    Curr Opin Infect Dis; 2007 Dec; 20(6):568-73. PubMed ID: 17975405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Searching for Staphylococcus aureus strains with reduced susceptibility to glycopeptides among clinical isolates obtained during the year of 2002].
    Młynarczyk A; Młynarczyk G; Łuczak M
    Med Dosw Mikrobiol; 2003; 55(3):209-17. PubMed ID: 14702662
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Surveillance of antibacterial resistance in Staphylococcus aureus isolated in Kuwaiti hospitals.
    Udo EE; Al-Sweih N; Dhar R; Dimitrov TS; Mokaddas EM; Johny M; Al-Obaid IA; Gomaa HH; Mobasher LA; Rotimi VO; Al-Asar A
    Med Princ Pract; 2008; 17(1):71-5. PubMed ID: 18059105
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Update: Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1997 Sep; 46(35):813-5. PubMed ID: 9310213
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus.
    Appelbaum PC
    Clin Microbiol Infect; 2006 Mar; 12 Suppl 1():16-23. PubMed ID: 16445720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Screening for Staphylococcus aureus with a reduced susceptibility to vancomycin in: a Belgian hospital].
    Piérard D; Vandenbussche H; Verschraegen I; Lauwers S
    Pathol Biol (Paris); 2004 Oct; 52(8):486-8. PubMed ID: 15465269
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduced susceptibility of Staphylococcus aureus to vancomycin--Japan, 1996.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1997 Jul; 46(27):624-6. PubMed ID: 9218648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children.
    Kaplan SL; Afghani B; Lopez P; Wu E; Fleishaker D; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
    Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S178-85. PubMed ID: 14520144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.
    Madrigal AG; Basuino L; Chambers HF
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3163-5. PubMed ID: 16048918
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage.
    Alós JI; García-Cañas A; García-Hierro P; Rodríguez-Salvanés F
    J Antimicrob Chemother; 2008 Oct; 62(4):773-5. PubMed ID: 18552338
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
    Jacqueline C; Caillon J; Le Mabecque V; Miègeville AF; Hamel A; Bugnon D; Ge JY; Potel G
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3397-400. PubMed ID: 17591849
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vascular graft infection by Staphylococcus aureus: efficacy of cefazolin, teicoplanin and vancomycin prophylaxis protocols in a rat model.
    Atahan E; Gul M; Ergun Y; Eroglu E
    Eur J Vasc Endovasc Surg; 2007 Aug; 34(2):182-7. PubMed ID: 17481929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Impact of methicillin resistance in S. aureus].
    Talon D
    Pathol Biol (Paris); 1999 Oct; 47(8):819-26. PubMed ID: 10573702
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 70.